KEGG   DRUG: TildrakizumabHelp
Entry
D10400                      Drug                                   

Name
Tildrakizumab (USAN);
Tildrakizumab (genetical recombination) (JAN)
Product
Formula
C6426H9918N1698O2000S46
Exact mass
144345.3728
Mol weight
144434.6737
Sequence
  Type
Peptide
Class
Other
 DG02019  Interleukin inhibitor
Remark
Product: D10400<US>
Efficacy
Antipsoriatic, Immunosuppressant, Anti-IL-23 antibody
Comment
Monoclonal antibody
Treatment of immunologically mediated inflammatory disorders
Target
IL23A [HSA:51561] [KO:K05426]
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL23A
     D10400  Tildrakizumab (USAN) <US>
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10400
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10400
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10400
BRITE hierarchy
Other DBs
CAS: 1326244-10-3
PubChem: 172232493
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system